ExodusPoint Capital Management’s Tyra Biosciences TYRA Stock Holding History

ExodusPoint Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$539K	Sell	14,066 -28,725	-67%	-$930K	﹤0.01%	1175
2025 Q4	$1.12M	Buy	+42,791	New	+$786K	0.01%	953
2025 Q3	–	Sell	-67,442	Closed	-$645K	–	2039
2025 Q2	$645K	Buy	67,442 +37,207	+123%	+$354K	0.01%	1079
2025 Q1	$281K	Buy	+30,235	New	+$391K	﹤0.01%	1244
2024 Q3	–	Sell	-170,717	Closed	-$2.73M	–	2113
2024 Q2	$2.73M	Sell	170,717 -101,433	-37%	-$1.75M	0.02%	668
2024 Q1	$4.46M	Buy	+272,150	New	+$4.46M	0.03%	430

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ExodusPoint Capital Management's TYRA Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Tyra Biosciences (TYRA) stake by 67% in Q1 2026, selling an estimated $930K and leaving 14,066 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #1175.

ExodusPoint Capital Management first reported a position in TYRA in Q1 2024 and has held it in 6 quarters since. The position peaked at $4.46M in Q1 2024. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

ExodusPoint Capital Management held 14,066 shares of Tyra Biosciences worth $539K as of Q1 2026.
ExodusPoint Capital Management sold 28,725 Tyra Biosciences shares in Q1 2026, an estimated $930K.
Tyra Biosciences made up ﹤0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1175 holding.
ExodusPoint Capital Management first reported a position in Tyra Biosciences in Q1 2024 and has held it in 6 quarters since.
ExodusPoint Capital Management's Tyra Biosciences position peaked at $4.46M in Q1 2024.
164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.